Pharming N.V.(US:PHAR)2026-04-02 10:03Revenue and Sales - RUCONEST® sales accounted for approximately 85% of total revenues in 2025, with expectations for continued dominance in future revenues [38]. - Joenja® has been commercialized in the U.S., U.K., Japan, Australia, and Israel, but its market acceptance remains critical for future success [32]. - Future revenue estimates are subject to uncertainties, including market acceptance and regulatory developments [25]. - The company anticipates that 77% of its revenues in 2025 will come from two U.S. specialty pharmacies [46]. - Two U.S. customers accounted for $290.9 million, or 77%, of revenues for the year ended December 31, 2025, and $227.7 million, or 77%, for the year ended December 31, 2024 [97]. Competition and Market Dynamics - The company faces intense competition in the Hereditary Angioedema (HAE) market, with several approved products and new therapies in development [36]. - The potential for new prophylactic therapies in 2025 may reduce the demand for acute rescue medications like RUCONEST® [35]. - The development and commercialization of pharmaceuticals involve significant risks, including competition and regulatory challenges [33]. Regulatory and Compliance Issues - Regulatory approval for Joenja® in additional jurisdictions is a key focus, with plans for commercialization in those markets [19]. - The successful commercialization of products depends on adequate coverage and reimbursement from governmental authorities and health insurers [51]. - Regulatory changes, such as the introduction of Most-Favored-Nation pricing models, may lead to lower reimbursement rates for products [56]. - The company must comply with various federal and state healthcare laws, including anti-kickback statutes and false claims laws, which complicate business operations [145]. - The company faces significant penalties for non-compliance with healthcare laws, including civil and criminal penalties, which could adversely affect operations and financial results [143]. Manufacturing and Supply Chain Risks - The company relies heavily on third-party manufacturers for production, and any disruption could adversely affect sales and clinical trials [34]. - The company relies on a limited number of suppliers for essential materials, which exposes it to risks such as supply disruptions and price increases [90]. - The company has entered into manufacturing and supply agreements for Joenja® and RUCONEST® with third parties, and any interruption in supply could materially affect sales [96]. Intellectual Property and Patent Risks - The company currently holds over a hundred patent applications granted and pending in jurisdictions including the U.S., Europe, and Japan, which are crucial for protecting proprietary technology [108]. - There is uncertainty regarding the validity and enforceability of patents, which may affect the commercialization of current and future product candidates [109][112]. - The company may face litigation concerning intellectual property rights, which could result in significant liabilities and distract from business operations [111][115]. - If the company fails to obtain or maintain patent protection, it may face increased competition from generic versions of its products [114]. Financial and Economic Risks - The company is subject to significant tax risks, including potential financial loss and penalties due to changes in tax laws and practices [106][107]. - Adverse capital and credit market conditions could affect liquidity needs and the ability to finance operations [170]. - The company faces risks from general economic conditions, including inflation and supply disruptions, which could weaken demand for products [165]. Corporate Governance and Shareholder Issues - The company is subject to the Dutch Corporate Governance Code (DCGC) but does not comply with all best practice provisions, which may affect shareholder rights [195]. - Shareholders approved a proposal to exclude preemptive rights for up to 10% of issued share capital for general corporate purposes and for financing of mergers, acquisitions, and strategic alliances, each for a period of eighteen months [194]. - The company has never declared or paid dividends on its ordinary shares since listing on Euronext Amsterdam and does not anticipate paying dividends in the foreseeable future [196]. Strategic Focus and Development - Pharming Group is a global biotechnology company focused on developing therapies for rare and ultra-rare diseases with significant unmet needs [213]. - The company leverages proven clinical development and commercial infrastructure to expand its portfolio and increase access for patient communities [215]. - The company emphasizes patient insights and scientific community feedback in shaping its strategy and clinical study designs [214].